189 related articles for article (PubMed ID: 24115186)
1. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression.
Ricci E; Mattei E; Dumontet C; Eaton CL; Hamdy F; van der Pluije G; Cecchini M; Thalmann G; Clezardin P; Colombel M
Prostate; 2013 Dec; 73(16):1738-46. PubMed ID: 24115186
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.
Colombel M; Eaton CL; Hamdy F; Ricci E; van der Pluijm G; Cecchini M; Mege-Lechevallier F; Clezardin P; Thalmann G
Prostate; 2012 May; 72(7):713-20. PubMed ID: 21882211
[TBL] [Abstract][Full Text] [Related]
3. Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.
Hoogland AM; Verhoef EI; Roobol MJ; Schröder FH; Wildhagen MF; van der Kwast TH; Jenster G; van Leenders GJ
Prostate; 2014 May; 74(5):488-96. PubMed ID: 24375374
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer.
Eaton CL; Colombel M; van der Pluijm G; Cecchini M; Wetterwald A; Lippitt J; Rehman I; Hamdy F; Thalman G
Prostate; 2010 Jun; 70(8):875-82. PubMed ID: 20127735
[TBL] [Abstract][Full Text] [Related]
5. Activation of c-MET induces a stem-like phenotype in human prostate cancer.
van Leenders GJ; Sookhlall R; Teubel WJ; de Ridder CM; Reneman S; Sacchetti A; Vissers KJ; van Weerden W; Jenster G
PLoS One; 2011; 6(11):e26753. PubMed ID: 22110593
[TBL] [Abstract][Full Text] [Related]
6. Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow.
Jung Y; Decker AM; Wang J; Lee E; Kana LA; Yumoto K; Cackowski FC; Rhee J; Carmeliet P; Buttitta L; Morgan TM; Taichman RS
Oncotarget; 2016 May; 7(18):25698-711. PubMed ID: 27028863
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of katanin p60 in prostate cancer bone metastasis.
Ye X; Lee YC; Choueiri M; Chu K; Huang CF; Tsai WW; Kobayashi R; Logothetis CJ; Yu-Lee LY; Lin SH
Prostate; 2012 Feb; 72(3):291-300. PubMed ID: 21681775
[TBL] [Abstract][Full Text] [Related]
8. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.
Som A; Tu SM; Liu J; Wang X; Qiao W; Logothetis C; Corn PG
Br J Cancer; 2012 Oct; 107(9):1547-53. PubMed ID: 23033003
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of FAM84B during prostate cancer progression.
Wong N; Gu Y; Kapoor A; Lin X; Ojo D; Wei F; Yan J; de Melo J; Major P; Wood G; Aziz T; Cutz JC; Bonert M; Patterson AJ; Tang D
Oncotarget; 2017 Mar; 8(12):19218-19235. PubMed ID: 28186973
[TBL] [Abstract][Full Text] [Related]
10. Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients.
Li Q; Li Q; Nuccio J; Liu C; Duan P; Wang R; Jones LW; Chung LW; Zhau HE
Prostate; 2015 Sep; 75(12):1312-21. PubMed ID: 25990623
[TBL] [Abstract][Full Text] [Related]
11. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Lin SH; Lee YC; Choueiri MB; Wen S; Mathew P; Ye X; Do KA; Navone NM; Kim J; Tu SM; Yu-Lee LY; Logothetis CJ
Clin Cancer Res; 2008 Jun; 14(12):3729-36. PubMed ID: 18559590
[TBL] [Abstract][Full Text] [Related]
12. TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis.
Galoczova M; Nenutil R; Pokorna Z; Vojtesek B; Coates PJ
Virchows Arch; 2021 Apr; 478(4):627-636. PubMed ID: 33037932
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis.
Ye X; Huang X; Fu X; Zhang X; Lin R; Zhang W; Zhang J; Lu Y
J Hematol Oncol; 2023 May; 16(1):46. PubMed ID: 37138326
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
15. Mitotic quiescence, but not unique "stemness," marks the phenotype of bone metastasis-initiating cells in prostate cancer.
Wang N; Docherty F; Brown HK; Reeves K; Fowles A; Lawson M; Ottewell PD; Holen I; Croucher PI; Eaton CL
FASEB J; 2015 Aug; 29(8):3141-50. PubMed ID: 25888599
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
[TBL] [Abstract][Full Text] [Related]
17. Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.
Cackowski FC; Wang Y; Decker JT; Sifuentes C; Weindorf S; Jung Y; Wang Y; Decker AM; Yumoto K; Szerlip N; Buttitta L; Pienta KJ; Morgan TM; Taichman RS
Prostate; 2019 Oct; 79(14):1715-1727. PubMed ID: 31449673
[TBL] [Abstract][Full Text] [Related]
18. Carbohydrate-to-carbohydrate interactions between α2,3-linked sialic acids on α2 integrin subunits and asialo-GM1 underlie the bone metastatic behaviour of LNCAP-derivative C4-2B prostate cancer cells.
Van Slambrouck S; Groux-Degroote S; Krzewinski-Recchi MA; Cazet A; Delannoy P; Steelant WF
Biosci Rep; 2014 Sep; 34(5):. PubMed ID: 25137483
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma.
Martin TA; Jiang WG
Oncol Rep; 2014 Jan; 31(1):262-72. PubMed ID: 24173498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
